Corcept Therapeutics Incorporated resubmitted its New Drug Application to the U.S. Food and Drug Administration for relacorilant to treat Cushing's syndrome. Corcept Therapeutics is a biopharmaceutical company focused on developing and commercializing specialized medicine for endocrine and endocrine-related disorders.
